Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bonner

Showing results (221-230 of 318) with videos related to

Pageof 32
Sort By:
Cell Reports|November 9, 2017
CDK8 Kinase Activity Promotes GlycolysisMatthew D Galbraith, Zdenek Andrysik, Ahwan Pandey, et al.
The Oncologist|May 21, 2017
p16, HPV, and Cetuximab: What Is the Evidence?James A Bonner, Ricard Mesia, Jordi Giralt, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Gfi1 controls the formation of effector CD8 T cells during chronic infection and cancerOluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without CetuximabDavid I Rosenthal, Paul M Harari, Jordi Giralt, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2002
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiationDonald J Buchsbaum, James A Bonner, William E Grizzle, et al.
Anti-Cancer Drugs|December 1, 2005
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I studyMichael C Dobelbower, Suzanne M Russo, Kevin P Raisch, et al.
Nature Communications|May 15, 2025
Gfi1 controls the formation of effector-like CD8<sup>+</sup> T cells during chronic infection and cancerOluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram, et al.
Cancer|August 1, 1995
Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancerJ A Bonner, R T Eagan, V Liengswangwong, et al.
The Journal of Biological Chemistry|December 2, 2017
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageAsmi Chakraborty, Kaitlyn A Dorsett, Hoa Q Trummell, et al.
The Open Rheumatology Journal|September 18, 2013
The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH CohortTristan A Boyd, A Bonner, C Thorne, et al.
Pageof 32

Showing results (221-230 of 318) with videos related to

Sort By:
Pageof 32
Cell Reports|November 9, 2017
CDK8 Kinase Activity Promotes GlycolysisMatthew D Galbraith, Zdenek Andrysik, Ahwan Pandey, et al.
The Oncologist|May 21, 2017
p16, HPV, and Cetuximab: What Is the Evidence?James A Bonner, Ricard Mesia, Jordi Giralt, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Gfi1 controls the formation of effector CD8 T cells during chronic infection and cancerOluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without CetuximabDavid I Rosenthal, Paul M Harari, Jordi Giralt, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2002
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiationDonald J Buchsbaum, James A Bonner, William E Grizzle, et al.
Anti-Cancer Drugs|December 1, 2005
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I studyMichael C Dobelbower, Suzanne M Russo, Kevin P Raisch, et al.
Nature Communications|May 15, 2025
Gfi1 controls the formation of effector-like CD8<sup>+</sup> T cells during chronic infection and cancerOluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram, et al.
Cancer|August 1, 1995
Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancerJ A Bonner, R T Eagan, V Liengswangwong, et al.
The Journal of Biological Chemistry|December 2, 2017
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageAsmi Chakraborty, Kaitlyn A Dorsett, Hoa Q Trummell, et al.
The Open Rheumatology Journal|September 18, 2013
The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH CohortTristan A Boyd, A Bonner, C Thorne, et al.
Pageof 32